PsychopharmINFO Home
 HOME
PPI Index-Prozac

[Click here to subscribe to our weekly newsletter!!]


Fluoxetine (Prozac, Prozac Weekly, Sarafem)

Monthly Archives of Research Articles

Month
News
Items
Pubmed
Articles

Highlights

August 2003
08.17.03 [396]
08.10.03 [508]
08.03.03 [475]
click
Click here to go to our six-month Anniversary Issue #26 (08/04/03) of our members-only weekly newsletter!!
July 2003
07.27.03 [393]
07.20.03 [292]
29
June 2003
27
May 2003
38
April 2003
35
March 2003
38
February 2003
29
drivingalcohol withdrawalOCDGABA-A receptors5HT-1A receptorspoststroke motor functionaggressionneonatal exposure
INTERACTIONS: generalcocaine/dopaminezaprinastCYP2D6haloperidol/Haldolallopregnanolone
SFX: weight gainsexualwithdrawalagitationinsomniaabnormally enlarged breasts (gynecomastia)prolactinextrapyramidalcardiac/QTc
January 2003
01.26.03
01.19.03
01.12.03
01.05.03
30
killing cancer cells: Burkitt lymphoma treatment?aggression [animal]cocaine useborderline personality disorderin animal model of depression [rat]selective mutismbrain growth factor needed for antidepressant effecteating disorder
INTERACTIONS: estrogen hormonesolanzapine/Zyprexavalproic acid/Depakotetramadol/Ultram
SFX: anxiety [rat]sexual dysfunction in women
TRIALS: with olanzapine/Zyprexa for psychotic depression [n=27 OL]vs psychotherapy [n=450 DBPC]adult ADHD in cocaine users [n=19 OL]
December 2002
12.29.02
12.22.02
12.15.02
12.08.02
12.01.02
28
fibromyalgiasweating in social anxietyOCDprobing mechanisms of actionbrain levels of serotonin and norepinephrine (rat)migrainesgenetic predictors of responsestereoselective effects (rat)
INTERACTIONS: phencyclidine/PCP and NMDA receptorsP450 effects (rat)phototherapy5HT-2 antagonists (animal)
SFX: emotional bluntingsleep, driving performancerash
November 2002
11.17.02
11.10.02
11.03.02
45
review: premenstrual dysphoric disorder (PMDD)eating disordersbody dysmorphic disorderprobing the mechanisms of depression responsedual action antidepressants better (rats)vs turmeric (Curcuma longa) (mice)
INTERACTIONS: pharmacokinetics in childrenheparin/Lovenoxpimozide/Orap
SFX: review: suicidal ideationbleedingseizures (rats)
TRIALS: primary care: treatment of cancer-related depression by algorithm [n=35 OLPC]OCD in children and adolescents [n=43 OLPC]binge-eating [n=60 DBPC]premenstrual dysphoric disorder (PMDD) [n=108 OLPC]autism [n=129 OL]no effects on child after fetal exposure [n=122 OL]
October 2002
10.20.02
10.13.02
10.06.02
33
speed of onsetpostnatal depression and breast milkdepression during pregnancy
INTERACTIONS: amantadine in ratsamphetamine
SFX: hyponatremia and 2D6weight loss in ratsmanic sx in adults with learning disabilities
TRIALS: vs tianeptine [n=178 DB; n=387 DB]sleep and anxiety in depression, vs dothiepine [n=125 DB]pediatric depression [n=219 DBPC]preventing PTSD relapse [n=131 DBPC]
September 2002
09.29.02
09.22.02
09.08.02
09.01.02
33
blood levelsbreast milkPMDD (premenstrual dysphoric disorder)adding CBT for OCDR-fluoxetinetransporter-binding: R-fluoxetine vs escitalopram/Lexapro vs other SSRIsdecrease in impulsive behavior in pigeonsvs St John's wortpersonality disorder symptoms
INTERACTIONS: oral contraceptives (birth control pills) and unplanned pregnancy
SFX: sexual
TRIALS: relapse risk: with or without cognitive therapy [n=132 OL]for depression w/anxiety [n=123 OL]for PMDD: 10 vs 20 mg [n=260 SBPC]for depressed methadone maintenance patients [n=49 DBPC]
August 2002
08.25.02
08.11.02
08.04.02
29
pregnancyprescriptionscholesterol and response ratememorytreatment-resistant depressiontics
INTERACTIONS: P450 2D6 inhibitiontramadol/Ultramrisperidone/Risperdal
SFX: maniawithdrawal symptoms (vs paroxetine/Paxil)
TRIALS: depression and anxiety (vs venlafaxine/Effexor) [n=1454 DBPC]smoking [n=989 DBPC]vs reboxetine [n=381 DBPC]augmentation with lithium or desipramine [n=101]
July 2002
07.28.02
07.21.02
07.14.02
07.07.02
39
marketingPMDD (premenstrual dysphoric disorder)in atypical antipsychotic-induced weight gainbeta-1 receptorsregulation of serotonin releaseserotonin-1A receptorsaugmentation with olanzapine/Zyprexa for psychotic depressionaugmentation with olanzapine/Zyprexa for treatment-resistant depressionvs sertraline/Zoloftmaniastress responsefor autismfor aggressionaugmentation with NMDA antagonists amantadine/Symmetrel and memantine/Ebixacocaine dependence
INTERACTIONS: Ecstacy/MDMAolanzapine/Zyprexaprogesterone
SFX: sexualurinary retentionlearningweight
TRIALS: vs venlafaxine/Effexor [n=146 DB]vs venlafaxine/Effexor for depressionclonazepam augmentation [n=50 DBPC]Prozac Weekly in depression relapse [n=501 DBPC]
June 2002

20
for premenstrual dysphoric disorderblood levelspredicting responseneuropeptide Y5HT1B receptorsfor childhood depression
INTERACTIONS: loratadine/Claritintramadol/Ultramphentermine/Adipex
SFX: sexualweight lossextrapyramidal
May 2002

42
suicide preventionserotonin receptorsestrogen augmentation in perimenopausal depressioneffect on cholinesterasesin post-traumatic OCDversus placebo in brain metabolismtreatment response relates to genetic variability of serotonin transporter
INTERACTIONS: codeineselegiline/Eldeprylcaffeinerisperidone/Risperdal
SFX: tremorserotonin syndrome
TRIALS: geriatric depression [n=242 DBPC]prevention of poststroke depression [n=48, DBPC]versus St. John's wort [n=70 , DBPC]anxious depression [n=22 DBPC]social anxiety disorder [n=60 DBPC]
April 2002

40
comparing SSRIsfor strokeswitching to Prozac Weeklyincrease in brain growth factoritching in polycythemia vera
INTERACTIONS: St. John's wort and gingkoECTadding bupropion/Wellbutrin
SFX: rashwithdrawallow sodium
TRIALS: premenstrual dysphoric disorderbody dysmorphic disorderPTSDdepression [review]
March 2002

43
February 2002

22
January 2002

52

---ALL 2001---


401
December 2001

22
November 2001

23


[n=number of subjects in study. OL=open label (nonblinded). SB=single-blind. DB=double-blind. PC=placebo control. SFX=side effects]

L10 Web Stats Reporter 3.1 L10 Hit Counter - Free Web Statistics
LevelTen Web Design - Flash, Website Designers